• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: GALDERMA Q-MED AB SOLESTA; AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

GALDERMA Q-MED AB SOLESTA; AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE Back to Search Results
Lot Number UNKNOWN
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Cyst(s) (1800); Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Type  Injury  
Manufacturer Narrative
Product note: routine investigations have been performed and provide sufficient information to assess the potential root cause and indicate a possible association to the treatment procedure.The lot number was not reported and could not verify the reported product.The information in this case does not indicate a non-conforming product or malfunction.The performed investigations are therefore considered adequate and no additional investigations will be conducted.Company comment: the serious event of implant site cyst and the non-serious event of device dislocation were considered expected and possibly related to the treatment.Seriousness criteria include the need for surgical intervention to prevent permanent damage.The potential root cause includes treatment procedure.The case meets the seriousness criteria for expedited reporting to the regulatory authorities.
 
Event Description
Case reference number (b)(4) is a literature report detected on 20-oct-2021.The case report was described in zhu c, matz r, lewin-smith m, strausborger s, wohltmann w.Migrated bulking material (solesta) presenting as a vaginal "cyst": histopathologic and chemical analytical features.International journal of gynecological pathology.2021; 00 (1-4).Performing injections with a bulking agent consisting of nonanimal stabilized hyaluronic acid and dextranomer is a well-tolerated and efficacious treatment for mild to moderate fecal incontinence.Here, we discuss a case of a patient with a history of a bulking procedure for fecal incontinence who presented to the obstetrics/gynecology clinic for evaluation of a new vaginal "cyst," which was excised.Histopathologic examination revealed migrated bulking agent within the excised specimen.A (b)(6) african american female presented to the obstetrics/gynecology clinic for a new "vaginal cyst." she reported a 2 to 3mo history of a nontender, nondraining lesion in her left anterior-lateral vaginal wall, which was excised and sent for pathology.Routine hematoxylin & eosin staining demonstrated submucosal foreign/exogenous material composed of weakly basophilic, irregularly shaped, gel like sheets, and colorless to weakly eosinophilic, round, refractile material with interspersed granular, fibrinoid eosinophilic debris, macrophages, and occasional "foreign body"-type multinucleated giant cells.The basophilic, irregularly shaped material (hyaluronic acid/hyaluronate) stained with mucicarmine while the round objects (dextran/dextranomer) did not.The basophilic material did not stain with periodic acid schiff with diastase while the round objects (dextran/dextranomer) did.Acid mucopolysaccharide stained both the basophilic and round material.The basophilic material was almost entirely removed by hyaluronidase while the round material remained when stained with acid mucopolysaccharide with hyaluronidase.The histochemical findings supported the presence of a material composed of 2 components, one of which was consistent with hyaluronic acid/hyaluronate.Hyaluronic acid has been used as a dermal filler commonly for cosmetic purposes on the face and less commonly in other locations, to include the vagina.A thorough review of the patient's medical records failed to show a history of cosmetic procedures but did reveal a long history of fecal incontinence for which she had undergone a bulking procedure with solesta, which is composed of dextranomer and hyaluronic acid.On scanning electron microscopy/energy dispersive x-ray analysis the material consisted of carbon (c) and oxygen (o) showing slightly elevated oxygen (o) as compared with tissue.This nonspecific finding is consistent with hyaluronic acid and dextranomer along with other materials.Infrared spectroscopy was subsequently performed.Spectra obtained from the authentic sample of solesta was compared with spectra from the foreign material in an unstained tissue section mounted on an aluminized slide.Accounting for the spectral peaks from background tissue protein, the spectra obtained from the foreign material are consistent with spectra obtained from the authentic sample of solesta.Using scanning electron microscopy/energy dispersive x-ray analysis, a technique for elemental analysis, and infrared spectroscopy, a method of molecular characterization of unknown materials which uses comparisons to spectra of known authentic samples, the "vaginal cyst" in our case was consistent with a pool of solesta from a prior bulking procedure.Pathologists should be aware that hyaluronic acid is used in the treatment of fecal incontinence and should consider the possibility that unusual mucicarminophilic material associated with a "foreign body"-type reaction may represent material that has migrated from the deep submucosal tissue planes of the anal canal into the vaginal wall.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SOLESTA
Type of Device
AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
Manufacturer (Section D)
GALDERMA Q-MED AB
seminariegatan 21
uppsala, SE-75 228
SW  SE-75228
Manufacturer (Section G)
GALDERMA Q-MED AB
seminariegatan 21
uppsala, SE-75 228
SW   SE-75228
Manufacturer Contact
randy russell
14501 north freeway
fort worth, TX 76177
MDR Report Key12844302
MDR Text Key285944744
Report Number9710154-2021-00073
Device Sequence Number1
Product Code LNM
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P100014
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Literature,Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 11/19/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 10/20/2021
Initial Date FDA Received11/19/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Unknown
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age57 YR
Patient SexFemale
-
-